These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 8935843

  • 21. Long-term effects of finasteride on prostate tissue composition.
    Marks LS, Partin AW, Dorey FJ, Gormley GJ, Epstein JI, Garris JB, Macairan ML, Shery ED, Santos PB, Stoner E, deKernion JB.
    Urology; 1999 Mar; 53(3):574-80. PubMed ID: 10096387
    [Abstract] [Full Text] [Related]

  • 22. Assessment of the patient with benign prostatic hyperplasia.
    Carlin BI, Resnick ML.
    Compr Ther; 1996 Sep; 22(9):586-91. PubMed ID: 8902350
    [No Abstract] [Full Text] [Related]

  • 23. [Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine].
    Loran OB, Pushkar' DIu, Rasner PI.
    Urologiia; 2002 Sep; (1):19-22. PubMed ID: 11877966
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Prostate cancer prevention and finasteride.
    D'Amico AV, Barry MJ.
    J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Re: A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride.
    Harrison RH.
    J Urol; 2000 Nov; 164(5):1670-1. PubMed ID: 11203073
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
    Granados Loarca EA.
    Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia.
    Kearney MC, Bingham J, Bergland R, Meade-D'Alisera P, Puchner PJ.
    J Urol; 2002 Jun; 167(6):2489-91. PubMed ID: 11992064
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F, Alcaraz A, Desgrandchamps F, Hammerer P, Schröder F, Castro R.
    Prostate; 2009 Jun 01; 69(8):895-907. PubMed ID: 19267353
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr 01; 22(2):389-402. PubMed ID: 18471794
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.